AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05328713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
Study NCT04963309 — intervention group
Intervention type: OTHER
Intervention: endotracheal tube extubation in the operating room
Description: endotracheal tube extubation in the operating room
Study NCT04820803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE
Description: one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
Study NCT04820803 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: one mouthwash containing distilled (placebo) water for 60 seconds
Study NCT04351178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone supported and team based rehabilitation
Description: Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
Study NCT04351178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation as usual
Description: Control group participants will receive rehabilitation as usual and in addition information about stroke.
Study NCT06196060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual perspective taking training
Description: Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.
Study NCT06196060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Block building training
Description: Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.
Study NCT06196060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thought-bubble training
Description: Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.
Study NCT06196060 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Participants will continue to receive treatment as usual during the trial.
Study NCT06367829 — intervention group
Intervention type: PROCEDURE
Intervention: Lubinus SPII hip stem 130mm
Description: Shorter length of the SPII hip stem
Study NCT06367829 — intervention group
Intervention type: PROCEDURE
Intervention: Lubinus SPII hip stem 150mm
Description: Longer length of the SPII hip stem
Study NCT06254248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept.
Study NCT05385068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle
Study NCT05011500 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Closed Mask
Description: Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.
Study NCT05011500 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Open Mask and Surface Scanning
Description: Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
Study NCT05011500 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with No Mask
Description: Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
Study NCT06485219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.2 mg/m2 Purinostat Mesylate
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Study NCT06485219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg/m2 Purinostat Mesylate
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Study NCT05233280 — intervention group
Intervention type: OTHER
Intervention: Oral liquids and soft food 2 hours postoperative
Description: Early versus delayed oral liquid feeding after ceasarean section
Study NCT04764565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun Instant
Description: Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
Study NCT04764565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: water
Study NCT04764565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: water
Study NCT04764565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun Electrolyte
Description: Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
Study NCT05077566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at 60% vo2
Description: 15 minutes of exercise at 60% VO2 max.
Study NCT05077566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise at 90% vo2
Description: 15 minutes of exercise at 90% VO2 max.
Study NCT06325189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training
Description: Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
Study NCT04366336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
Study NCT04366336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
Study NCT05493176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study NCT04804800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1 : Virtual Reality
Description: Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
Study NCT04804800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2 : Virtual Reality + Multi Sensorial Remediation
Description: Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
Study NCT04316312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer
Description: Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
Study NCT05411536 — intervention group
Intervention type: OTHER
Intervention: Walking trials
Description: All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order.
Study NCT06015126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic oral vinorelbine plus anlotinib
Description: To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
Study NCT05749133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GPRC5D CAR-T Cells Injection
Description: This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based.
Study NCT04631770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic mediastinal lymph node dissection
Description: Systematic hilar and mediastinal lymph node dissection.
Study NCT04631770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spared mediastinal lymph node dissection
Description: Mediastinal lymph node is spared in this group.
Study NCT04854148 — intervention group
Intervention type: OTHER
Intervention: Smartphone Movement Health Assessment
Description: Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
Study NCT06378619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tapping Test
Description: For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
Study NCT06378619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Archimedes Spiral
Description: For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.
Study NCT04219501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIVO
Description: Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
Study NCT05951049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT02
Description: Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
Study NCT06369805 — intervention group
Intervention type: OTHER
Intervention: there is no intervention
Description: there is no intervention
Study NCT04788238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Zumba Gold
Description: Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
Study NCT04855981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
Study NCT04855981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
Study NCT04855981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supplementation
Description: the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
Study NCT04855981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplementation
Description: the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
Study NCT05919966 — intervention group
Intervention type: OTHER
Intervention: Chlorhexidine bathing
Description: The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
Study NCT04617769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: psychoeducational materials on trauma and safety behaviors
Study NCT04617769 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: psychoeducational materials on trauma and safety behaviors
Study NCT04617769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: psychoeducational materials on trauma and safety behaviors
Study NCT04617769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: six 3-minute video exposure trials with an inter-trial interval of 2 minutes
Study NCT04617769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: six 3-minute video exposure trials with an inter-trial interval of 2 minutes
Study NCT05697471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: Dienogest 2 mg per day
Study NCT05697471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danzol 200MG per day
Study NCT05269381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05269381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptide Vaccine
Description: Receive personalized neoantigen vaccine SC
Study NCT05269381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05269381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT04872257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D
Description: Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
Study NCT04872257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NB-UVB Phototherapy
Description: NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
Study NCT04872257 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NB-UVB Phototherapy
Description: NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
Study NCT04872257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for 6 months
Study NCT06229925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Stimulation
Description: Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.
Study NCT06229925 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
Study NCT04875793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups
Description: participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
Study NCT05756530 — intervention group
Intervention type: OTHER
Intervention: Affective touch paradigm
Description: Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships.